ImClone Board Members Demand Control Premium From Icahn
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest salvo from Icahn prompts board to ask shareholders to reject billionaire’s demands.
You may also be interested in...
Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns
Firm searches for new CEO with biotech, drug development and commercialization experience.
Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns
Firm searches for new CEO with biotech, drug development and commercialization experience.
Icahn Gets Wish With Departure Of ImClone’s Kies, But Will Door Open To Him?
Billionaire and his allies hold 40% of the biotech’s board, possibly leading to further changes.